share_log

复星医药(600196.SH):控股子公司签署许可协议

FOSUN PHARMA (600196.SH): A subsidiary has signed a licensing agreement.

Gelonghui Finance ·  Dec 19, 2024 02:11

Gelonghui, December 19 - FOSUN PHARMA (600196.SH) announced that on December 19, 2024, its holding subsidiary HENLIUS signed a "Cooperation and License Agreement" with Palleon. According to the agreement, both parties will collaborate on the global development of Palleon’s investigational product E-602 and related combination therapy solutions within the field (i.e., for the treatment of human diseases) based on their respective patents and proprietary technologies, and will carry out commercialization in their respective licensed areas.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment